The Motley Fool
20 Nov 2026, 20:36 UTC · 52m ago
Revolution Medicines Drugged a Target Scientists Called “Undruggable” for Decades. Buy the Stock Hand Over Fist?
Impact · against what's priced in
The strong initial launch and Phase 3 results for Rasonque are already reflected in RVMD's current valuation, providing no new catalyst. The broader market decline for mega-cap tech is a separate macroeconomic event not driven by the contents of this article.
- NVDA+0.00
Doesn't touch the price's assumptions
- In context
The article mentions the stock price in a market data table, but the content is about oncology and does not impact AI hardware demand or Blackwell revenue.




